{"links":{"html":"https://www.erudio.com/reports/saron-nct02417662","json":"https://www.erudio.com/reports/saron-nct02417662.json","markdown":"https://www.erudio.com/reports/saron-nct02417662.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"saron-02417662"}},"request":"https://www.erudio.com/contact?report=saron-02417662"},"offer":{"cited_commentary_sources":30,"verified_hcp_statements":156,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":40,"optional":true,"price_per_verified_person_usd":15,"price_usd":600,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"saron-nct02417662"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=saron-02417662","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/saron-nct02417662","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified HCP statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-17T15:44:02.705029Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":8,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: Overall Survival"},{"claim_count":13,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":25,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":28,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":12,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":31,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":13,"title":"Design and conduct"},{"claim_count":18,"coverage":"discussed","id":"A1","source_count":8,"title":"Biological selection, disease tempo and generalizability"},{"claim_count":11,"coverage":"discussed","id":"A2","source_count":6,"title":"Completeness of treatment, staging and lesion-level coverage"},{"claim_count":15,"coverage":"discussed","id":"A3","source_count":9,"title":"Systemic-treatment era, sequencing and repeated local intervention"},{"claim_count":23,"coverage":"discussed","id":"A4","source_count":11,"title":"Clinical uptake, equipoise and access to comparative evidence"},{"claim_count":24,"coverage":"discussed","id":"A5","source_count":13,"title":"Interpretation of incomplete results and anticipated SARON impact"}],"counts":{"cited_sources":30,"claims_by_expression_type":{"comparison":17,"experience":7,"interpretation":21,"opinion":31,"primary_context":3,"question":23,"restatement":23,"uncertainty":16,"unspecified":15},"claims_by_kind":{"attributed_opinion":18,"interpretation":4,"source_observation":134},"evidence_units":138,"findings":9,"people_cited":44,"people_identity_verified":40,"people_total":41,"screened_sources":41,"verified_claims":156},"depth":"rich","findings_index":[{"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":3,"experience":0,"questions":4,"restated":0,"views":4},"has_counterview":true,"limitations":3,"links":{"context":5,"support":11},"ma_question":true,"named_voices":4,"passages":10,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"A negative local-therapy study was not interpreted uniformly as a verdict on synchronous oligometastatic disease"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":1,"questions":4,"restated":0,"views":3},"has_counterview":true,"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":7,"passages":9,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Selection concerns extend beyond lesion count to biology, disease tempo and real-world applicability"},{"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":4,"passages":5,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Completeness of local treatment matters to clinicians, but the supporting observations require careful separation"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":2,"views":5},"has_counterview":true,"limitations":6,"links":{"context":3,"support":10},"ma_question":true,"named_voices":7,"passages":10,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Treating the primary: advocacy, modality choices and limits of acute-safety reassurance"},{"id":"F6","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":4,"restated":0,"views":2},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":5,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Systemic-treatment era and the intended role of local therapy remain central uncertainties"},{"id":"F7","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":1,"views":2},"has_counterview":true,"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":6,"passages":9,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"The endpoint debate is about meaningful added value, not simply whether PFS can improve"},{"id":"F8","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":1,"views":2},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":4,"passages":7,"sources":2,"sources_by_kind":{"commentary":2}},"title":"The LU002 progression threshold prompted a specific, unresolved statistical-design disagreement"},{"id":"F9","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":7,"passages":11,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Enthusiasm for local therapy was paired with equipoise, recruitment and evidence-completeness concerns"},{"id":"F10","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":5,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":10,"passages":13,"sources":10,"sources_by_kind":{"commentary":10}},"title":"SARON was repeatedly positioned as important forthcoming evidence, not as a known positive or negative result"}],"medical_affairs_question":"Which baseline disease states and post-induction patterns must be distinguished before discussing the applicability of SARON?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Distinguishing synchronous disease from induced oligopersistence"},{"id":"section-2","level":2,"title":"Patient selection beyond a lesion threshold"},{"id":"section-3","level":2,"title":"Complete treatment and adequate assessment of remaining disease"},{"id":"section-4","level":2,"title":"Treating the primary: strong advocacy, modality alternatives and dose questions"},{"id":"section-5","level":2,"title":"Acute safety: favorable feasibility appraisals and the broader therapeutic-ratio question"},{"id":"section-6","level":2,"title":"Systemic-treatment era, sequencing and the purpose of local therapy"},{"id":"section-7","level":2,"title":"Endpoints that demonstrate patient-relevant added value"},{"id":"section-8","level":2,"title":"Statistical thresholds and the decision to continue a trial"},{"id":"section-9","level":2,"title":"Equipoise, recruitment and completeness of the evidence conversation"},{"id":"section-10","level":2,"title":"Anticipation of SARON, without a known efficacy direction"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, na","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Survival"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F7","shared_claims":8},{"id":"F8","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":9},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":7},{"id":"F6","shared_claims":6}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":4}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":7},{"id":"F9","shared_claims":8},{"id":"F10","shared_claims":9}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-17T15:44:02.705029Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-17T15:48:55Z","record_hash":"b24f5b70e641a50ff18cf033ada0370de44a3e43edc49b0012c6c82fb6d2432e","release_hash":"911047668840ae30a75a252a0bf17dc0abb146955e0e65c13bd55ebc62da1232","report_id":"erudio-nct02417662","run_id":"f78efbed-b042-4e15-825c-bd9901ae4d19","schema_version":"5.0","slug":"saron-02417662","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"SARON asks whether adding radical radiotherapy to systemic treatment helps patients with synchronous oligometastatic non-small cell lung cancer. Clinicians discuss patient selection, disease at diagnosis versus limited residual disease after induction, and comparisons with related randomized studies. Other topics include systemic-treatment era and sequencing, treatment of the lung primary, local treatment options, safety, patient-relevant endpoints, and potential implications for practice. SARON's main results are scheduled for ESMO 2026; this report reflects commentary before that presentation.","meta_description":"41 sources screened · 156 verified HCP statements from 30 sources · 9 findings. Updated Oct 17, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-7e622aca718225bc6677"],"id":"F1","paraphrase":"A podcast speaker asked whether clinicians should continue treatment directed at oligometastatic disease or pause it while awaiting SARON results, in light of related trial evidence.","publication_caveats":{"reason":"Source-specific publication caveats are not stated.","status":"not_set"},"source_channel":"podcast","source_date":"2024-06-19","title":"A negative local-therapy study was not interpreted uniformly as a verdict on synchronous oligometastatic disease"},{"cited_claim_ids":["claim-367693574fbdddcd0339"],"id":"F6","paraphrase":"An X-thread participant asked whether SARON's findings might differ from related randomized evidence in the context of changing systemic treatment.","publication_caveats":{"reason":"Source-specific publication caveats are not stated.","status":"not_set"},"source_channel":"x_thread","source_date":"2024-06-02","title":"Systemic-treatment era and the intended role of local therapy remain central uncertainties"}]},"publication":{"approved_at":"2026-10-17T15:48:55Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":41},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 1 passage in the reviewed sources discusses other trials or topics outside this report's scope; it is not part of this edition.","12 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are not a representative sample of HCP opinion; neither source numbers nor repeated posts establish consensus.","Some potentially relevant posts and videos were unavailable, and searching mainly by trial names and identifiers may have missed unnamed or differently transcribed references.","Some passages may not have been fully assessed, so additional relevant qualifications or views may be absent.","Two comments relaying someone else's talk did not identify whose positions were being conveyed and cannot support attribution to a named clinician.","Several numerical study descriptions and results are clinicians' accounts of related trials, not independent extractions from complete trial reports.","The main SARON efficacy-results publication is not among the sources reviewed; anticipated effects on practice are expectations rather than observed implementation.","Anonymous panel responses are not assigned to people on a program or guest list. Professional credentials and identity confirmation are not equally available for all named authors.","Posts from different dates, settings or identically named accounts are not used to infer a change of mind or a longitudinal disagreement.","The two SARON thoracic sub-study safety posts use different severe-toxicity thresholds and do not establish late or whole-trial safety.","A full SARON protocol was not available in the reviewed material, limiting independent assessment of commentators' population and treatment comparisons."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":28,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":30},"count":30,"evidence_window":{"end":"2026-09-26","start":"2019-04-14"},"retrieval_snapshot":"2026-10-17T02:56:24.423453Z","timeline":[{"count":1,"week":"2019-W15"},{"count":1,"week":"2020-W07"},{"count":1,"week":"2020-W32"},{"count":1,"week":"2020-W33"},{"count":1,"week":"2022-W24"},{"count":1,"week":"2023-W12"},{"count":2,"week":"2023-W17"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W29"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W40"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2023-W50"},{"count":3,"week":"2024-W22"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W39"},{"count":2,"week":"2025-W19"},{"count":1,"week":"2025-W45"},{"count":4,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W39"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT02417662:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02417662:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:29666135","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7fd2e3","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8b4618","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:cb6199","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:dd530b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1117476600734527490:44714197-9a9e-4ede-8d40-6a2f882e4f0c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1292279735045820417:99834f26-fad5-4c61-8c40-fabb913da70b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1537441851434672130:302b6285-a4fe-4bf7-9b32-bf2f3e5021c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1633996399154003969:6fed19ae-e00c-492b-bf24-575d44bd7a55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1638961193170661387:644334bf-8a33-4bc2-bea8-7c093adcfa60","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1651924804558020609:29f46441-c829-43eb-b0cb-7b3bd002706d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1652350176156168193:0305bc6c-3d92-4a7d-96c4-e0debb51aa55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1663869652412379140:dc9079b4-f610-4e5c-b8c9-dba53a5e6eb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1664019671169785857:f50b9330-c186-4550-b8a4-78461a959815","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1681012653127266305:999be1e3-e73a-4e91-963c-7f28dae166d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701406907209236744:9ed83404-bac9-48bb-be29-81208bdd8a39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1706688847554514983:b8df083a-dd50-46c1-9efc-2e47686c1eb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1709231880284058020:d5a2b032-ed96-40db-a947-6c4b6cfe2e22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1732584886001713466:51d6ce22-50f0-47e8-ad67-c4973fc13e5d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1732592826829901831:9a81e383-86e5-4602-9c2d-f1a344ce11ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796705333462831536:3d216466-e88d-47d6-929b-468222e28d71","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797186046138175591:cb4d56c2-b624-42aa-93ac-be746baa8f76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797256966571532493:ec4c6b0d-7716-4b7d-b6c0-5dc3ac1fea62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1839860246908449251:80f83761-f2df-4efb-ba77-ee4dcc00e182","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1842210161852665995:e80c3671-7b9f-4260-be38-314605a817ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1920132621247336768:46c55057-7ca6-4862-bbae-adc0d4f583af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1920133389018911220:c879b7d0-82d3-424a-8344-79adec74e01d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1920137316024156533:f8b00f2f-1988-4030-9e65-8579748f65cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992650411874894288:1115e5a1-e3f9-40f3-9950-d3a61894c479","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992650967045612027:fce58253-8ffc-4c53-95e3-a9e98c88a239","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992652713692446876:a668ed23-f07b-4ef0-b9f5-e6e60f2f7e02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992652882353570204:24cddeb6-b3f1-43b5-9043-b7d97c846754","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047159714539086081:7abf348c-52ad-4e7b-ace6-f0e480863be9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2063993760367665474:9cd4cbff-c8ab-4166-96cd-082e990dca39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096213674977345967:53d9004c-a9cd-4c3d-94ca-b374fbd45695","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102539871277682768:2b6a64bf-bb76-4172-9d72-b21e7c06bab6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102759902930215274:460abf3b-2753-491c-a5ac-5b49a5e709da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103771064417358220:9abc37c5-ec85-4962-afaa-96e5c8ff2c29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107390688413339706:1995d6ed-bfaa-4508-be1b-17f7b6208056","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FvonN0gWSWo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:OuEsGdqGInM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vDxPWZtSU5A","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":34,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":41},"count":41,"evidence_window":{"end":"2026-10-06","start":"2019-04-14"},"retrieval_snapshot":"2026-10-17T02:56:26.915468Z","timeline":[{"count":1,"week":"2019-W15"},{"count":1,"week":"2020-W07"},{"count":1,"week":"2020-W32"},{"count":1,"week":"2020-W33"},{"count":1,"week":"2022-W24"},{"count":1,"week":"2023-W10"},{"count":1,"week":"2023-W12"},{"count":2,"week":"2023-W17"},{"count":1,"week":"2023-W20"},{"count":1,"week":"2023-W21"},{"count":3,"week":"2023-W22"},{"count":1,"week":"2023-W29"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W40"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2023-W50"},{"count":3,"week":"2024-W22"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2025-W08"},{"count":3,"week":"2025-W19"},{"count":1,"week":"2025-W45"},{"count":4,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W36"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: non-investigational sact","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"SARON","aliases":["SARON","Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer","Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase II Trial"],"brief_title":"Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer","collaborators":["Cancer Research UK"],"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":140,"type":"ACTUAL"},"interventions":[{"name":"Radical Radiotherapy (Conventional RT and SABR)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"Non-investigational SACT","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT02417662","official_title":"Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase II Trial","overall_status":"ACTIVE_NOT_RECRUITING","phase":["NA"],"primary_completion_date":{"date":"2026-09","type":"ESTIMATED"},"primary_endpoints":[{"description":"The trial will investigate the impact of the addition of radical conventional and stereotactic radiotherapy to standard systemic therapy on overall survival","measure":"Overall Survival","timeFrame":"From date of randomisation to the date of death, up to 36 months"}],"registry_last_updated":"2026-05-06","registry_url":"https://clinicaltrials.gov/study/NCT02417662","short_name":"SARON","short_name_basis":"registry_acronym","sponsor":"University College, London","start_date":{"date":"2016-08-19","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, na","study_ids":[{"id":"UCL/13/0594","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}